secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lantheus Holdings, Inc. (LNTH)
CIK:        0001521036
Form:       8-K
Filed at:   2025-04-01T23:59:59+00:00
Accession:  0001193125-25-069927
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 2.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lantheus closes $275M acquisition of Evergreen Theragnostics; adds OCTEVY and CDMO capabilities
--------------------------------------------------------------------------------

- Closed acquisition of Evergreen Theragnostics for $275M cash upfront ($250M + $25M milestone achieved pre-close).
- Additional contingent milestone payments up to $727.5M remain payable under the Merger Agreement.
- Acquisition adds OCTEVY, a registrational-stage PET imaging agent for neuroendocrine tumors.
- Adds Evergreen's radioligand therapy manufacturing infrastructure and revenue-generating CDMO business.
- CEO Brian Markison: acquisition enhances capabilities across the radiopharmaceutical value chain.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1521036/000119312525069927/0001193125-25-069927-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1521036/000119312525069927/d905401d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-069927

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer